News and Announcements
Actinogen Medical US Roadshow Investor Presentation July 2016
- Published July 15, 2016 12:03PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th July 2016, ASX Announcement
Focusing on an innovative approach, through the inhibition of cortisol production, for treating cognitive impairment in chronic neurodegenerative and metabolic diseases
Xanamem™: A prime investment opportunity
- Alzheimer’s – a significant unmet need in a huge and growing global market
- Xanamem™’s innovative, differentiated mechanism of action targeting the stress hormone cortisol
- Evidence Xanamem™ is both symptomatic and disease modifying
- Phase II study funded through to completion
- Patent protected to 2031 – composition of matter
- Value enhancing additional indications in substantive markets of interest to big pharmaceutical companies – Alzheimers disease, Diabetes, Parkinson’s disease
To view the full announcement, please click on the button below.
Company Updates
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
The Great Convergence: The $19 Trillion Shift Defining the Next Era of Wealth
A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Backed By Leading Investment Groups and Family Offices
